NEWTOWN, Pa.----CollaGenex Pharmaceuticals, Inc. today announced results of a Phase 2 dose-finding study designed to evaluate the safety and determine the therapeutic range of incyclinide for the treatment of rosacea.
From: biz.yahoo.com
CollaGenex Pharmaceuticals Announces Results of Phase 2 Dose-Finding Study of Incyclinide for the Treatment of Rosacea
Posted by Ruslan Abuzant at 4:57 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment